New Stock News | Qinhui Pharmaceutical Resubmits Application to the Hong Kong Stock Exchange; Revenue Soars to 560 Million Yuan in the First Five Months; GH31 Grants Gilead an $80 Million Initial Payment.

According to the Hong Kong Stock Exchange's disclosure on August 7, Qinhao Pharmaceutical (Suzhou) Co., Ltd. (referred to as Qinhao Pharmaceutical) has submitted a listing application to the main board of the Hong Kong Stock Exchange, with Huatai International serving as its sole sponsor. This marks the second time Qinhao Pharmaceutical has submitted a listing application to the main board following its initial filing in January 2026.